What does STGI mean in NASDAQ SYMBOLS

Steroidogenesis Inhibitor International was an international pharmaceutical company that focused on the research and development of drugs to inhibit steroidogenesis. It was de-listed in 2021.

The company's stock became illiquid, resulting in a decline in market capitalization, which eventually led to its de-listing.

The company specialized in the development of drugs which are designed to inhibit steroid production, such as anabolic steroids.

The company employed many experienced scientists and researchers who had experience in drug development, chemistry and biochemistry. It was headed by Dr. Gregory Schofield, who served as its Chief Executive Officer from 2019 until 2021.

Stopping steroid production can significantly reduce health risks associated with overproduction such as uncontrolled growth of organs or body structures, high blood pressure, depression, anxiety and other negative physical and mental side effects.

The products developed by Steroidogenesis Inhibitor were designed to target specific receptors involved in steroid production more precisely than existing medications on the market at the time. This allowed them to be more effective at inhibiting production while also reducing potential side effects.

Despite its de-listing, many pharmacies still had supplies of medications produced by Steroidogenesis Inhibitor available for patients who needed them. Additionally, generic versions of some drugs may have been available for those unable to afford brand name medicines at full price.

After de-listing, any remaining stocks became illiquid assets – meaning they could no longer be traded or sold on any exchanges or markets due to a lack of buyers or sellers willing to invest in them. As such their value has become almost zero over time.